Skip to main
PRQR

ProQR Therapeutics (PRQR) Stock Forecast & Price Target

ProQR Therapeutics (PRQR) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 80%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProQR Therapeutics NV is positioned favorably due to its focus on advancing RNA therapeutics for severe genetic rare diseases, with a pipeline that shows potential for expedited clinical advancement and proof of concept achievements. The Axiomer RNA base-editing platform is considered promising, with expectations for upcoming clinical data to enhance the company’s valuation. Successful execution in advancing its pipeline could significantly lead to stock price appreciation, indicating a robust outlook for investors.

Bears say

ProQR Therapeutics NV faces a negative outlook primarily due to the inherent risks associated with its Phase Ib/II/III clinical studies, which could significantly affect share performance based on their outcomes. Additionally, the company may encounter limited early revenue potential for its product AX-0810, given the smaller patient population it targets compared to its competitors, which could hinder growth prospects. Furthermore, the evolving landscape of treatment methods for genetic rare diseases poses a substantial threat, as successful new therapies may render ProQR's existing products non-competitive or obsolete.

ProQR Therapeutics (PRQR) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 80% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProQR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProQR Therapeutics (PRQR) Forecast

Analysts have given ProQR Therapeutics (PRQR) a Buy based on their latest research and market trends.

According to 5 analysts, ProQR Therapeutics (PRQR) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProQR Therapeutics (PRQR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.